Find uplifting stories about heroes, innovations, and solutions
106 results for "moderna"
A personalized mRNA cancer vaccine developed by Moderna and Merck has shown remarkable success in preventing melanoma from returning. The breakthrough sent Moderna's stock soaring 90% and offers new hope for treating cancer beyond COVID vaccines.
Mexico signed a groundbreaking agreement with Moderna to manufacture mRNA vaccines domestically, including potential vaccines for dengue and cancer. The five-year partnership will transfer cutting-edge vaccine technology to Mexican facilities and support local scientific research.
A groundbreaking cancer vaccine from Moderna and Merck reduced the chances of melanoma returning after surgery in a major trial with over 1,100 patients. Even the company's own executives didn't believe it would work.
A personalized cancer vaccine using the same mRNA technology that powered COVID vaccines just proved it works in major trials, tripling Moderna's stock price in one day. For melanoma patients, it's the breakthrough they've been waiting for.
After rejecting Moderna's flu vaccine application just a week ago, the FDA reversed course and will now review the promising mRNA shot. The new technology could revolutionize how we protect ourselves from seasonal flu.
A personalized cancer vaccine from Moderna and Merck just succeeded in its first large-scale trial, cutting melanoma recurrence rates and bringing hope to thousands. The breakthrough could transform how we treat cancer within the next year.
A Moderna immunotherapy for melanoma continues to protect patients years after treatment, new data shows. The results bring hope for a cancer vaccine that could change how we fight one of the deadliest skin cancers.
Moderna has launched human trials for the first vaccine targeting the Bundibugyo Ebola strain devastating the Democratic Republic of Congo. Using proven mRNA technology from COVID-19, the company is racing to create protection where none currently exists.
Moderna has agreed to pay Roivant up to $2.25 billion to settle a patent lawsuit over its groundbreaking Covid-19 vaccine technology. The settlement could become one of the largest in patent history while keeping life-saving vaccine innovation moving forward.
A personalized mRNA cancer vaccine from Merck and Moderna has succeeded in Phase 3 trials, marking a major breakthrough in immunotherapy. The treatment, called intismeran autogene, tailors cancer-fighting instructions to each patient's unique tumor.
A personalized cancer vaccine from Moderna and Merck just proved it can train your immune system to fight melanoma tumors with pinpoint accuracy. Thousands of patients could benefit within years, with trials already underway for lung, pancreatic, and colon cancers.
A new flu vaccine using the same technology that powered COVID shots just proved more effective than traditional options in a 40,000-person study. The breakthrough could reshape how we protect ourselves from seasonal flu.
A new personalized cancer vaccine using mRNA technology has shown remarkable results in preventing melanoma from returning after surgery. The breakthrough could open doors for similar treatments across dozens of other cancers.
After a century of failed attempts, a personalized mRNA cancer vaccine has successfully completed late-stage trials in melanoma patients. The treatment trains each person's immune system to fight their unique tumor mutations.
A groundbreaking mRNA cancer vaccine has shown promising results in preventing melanoma from returning after surgery, marking the first successful late-stage trial of its kind. The same technology behind COVID-19 vaccines could soon help thousands of cancer patients stay disease-free. #
A personalized cancer vaccine using mRNA technology just helped melanoma patients live longer without their cancer returning. The breakthrough treatment could become the first of its kind approved for cancer care.
A $60 million global health initiative is rushing three new vaccine candidates to combat a deadly Ebola outbreak in the Democratic Republic of Congo. The same mRNA technology that helped end the COVID-19 pandemic could now save lives in Central Africa.
A personalized cancer vaccine from Merck and Moderna just crushed its first late-stage trial, keeping melanoma patients cancer-free significantly longer than current treatment alone. The breakthrough validates decades of research into custom-made cancer fighters tailored to each patient's unique tumor.
The FDA suddenly agreed to review Moderna's revolutionary mRNA flu vaccine after initially rejecting it just a week earlier. Meanwhile, scientists developed an inhaled vaccine that could protect against multiple respiratory illnesses at once.
After an unexpected rejection last week, the FDA has reversed course and agreed to review Moderna's new mRNA flu vaccine. Seniors could have a new option to protect against the flu by late 2026.
Showing 20 of 106